Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Patients with Chronic Lymphocytic Leukemia Belonging to the B-Cell Receptor Stereotypy Subset #2 Have Long Progression Free Survival after Chemo- or Chemoimmunotherapy in the HOVON68 Trial

Fie Juhl Vojdeman, MD, Lone Bredo Pedersen, Doreen Te Raa, MD PhD, Vesa Juvonen, PhD, Yvette Norden, Geir Erland Tjønnfjord, MD DMsc, Eva Kimby, Maija Itälä-Remes, MD PhD, Anton W Langerak, Ludo M. Evers, Thorsten Zenz, MD, Marinus H.J. Van Oers, MD PhD, Christian H. Geisler, MD PhD, Arnon P. Kater, MD, Carsten Utoft Niemann, MD PhD

Blood (2017) 130 (Supplement 1): 4312.

https://doi.org/10.1182/blood.V130.Suppl_1.4312.4312

Published: 2017

Journal Articles

Alpha1-Antichymotrypsin Present in Therapeutic C1-Inhibitor Products Competes with Selectin - Sialyl Lewis X Interaction

Ruchira Engel, PhD, Laura Delvasto Nunez, Dorina Roem, Gerard van Mierlo, Stephanie Holst, Marinus H.J. Van Oers, MD PhD, Manfred Wuhrer, Prof, Diana Wouters, PhD, Sacha Zeerleder, MD PhD

Blood (2015) 126 (23): 1008.

https://doi.org/10.1182/blood.V126.23.1008.1008

Published: 2015

Journal Articles

Individual Patient Data (IPD) Meta-Analysis of Rituximab Maintenance (MR) for Patients (pts) with Follicular Lymphoma (FL)

Liat Vidal, MDMSc, Anat Gafter-Gvili, MD, Gilles Salles, MDPhD, Sami Bousseta, Bernice Oberman, Carmit Rubin, Marinus H.J. van Oers, MD PhD, Catherine Fortpied, Msc, Ruth Pettengell, MD, Peter Dreger, MD, Mathias Witzens-Harig, MD, Umberto Vitolo, MD, Andrea Evangelista, Maria Gomes da Silva, Hailun Li, Laurence Freedman, PhD, Thomas M Habermann, MD, Ofer Shpilberg, MD

Blood (2014) 124 (21): 4462.

https://doi.org/10.1182/blood.V124.21.4462.4462

Published: 2014

Journal Articles

R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation

Michel Van Gelder, PhD, MD, Wendim Ghidey, Martine ED Chamuleau, MD, Jan Cornelissen, MD, PhD, Eefke J Petersen, MD PhD, Simon M. G. J. Daenen, Pierre Zachee, MD, PhD, Mels Hoogendoorn, MD, PhD, Aart Beker, MD, Gert Jan Timmers, MD, PhD, Arnon P. Kater, MD PhD, Marinus H.J. Van Oers, MD, PhD

Blood (2013) 122 (21): 2883.

https://doi.org/10.1182/blood.V122.21.2883.2883

Published: 2013

Journal Articles

Possible Mechanisms Of Resistance To The Novel BH3-Mimetic ABT-199 In In Vitro Lymph Node Models Of CLL – The Role Of Abl and Btk

Rachel Thijssen, Christian R Geest, Martin FM de Rooij, Nora Liu, Bogdan I Florea, Katinka Weller, Hermen S Overkleeft, Marinus H.J. Van Oers, MD, PhD, Marcel Spaargaren, PhD, Arnon P. Kater, MD PhD, Eric Eldering, PhD

Blood (2013) 122 (21): 4188.

https://doi.org/10.1182/blood.V122.21.4188.4188

Published: 2013

Journal Articles

The Impact Of Subclonal Versus Clonal Novel Recurrent Mutations On Treatment Outcome In Previously Untreated High Risk CLL Patients: Results From The HOVON68 Trial

Doreen te Raa, MD, Arnon P. Kater, MD PhD, Wendim Ghidey Alemayehu, Alexander Jethwa, Jennifer Hullein, Eric Eldering, PhD, Tatjana Stankovic, MD, PhD, Thorsten Zenz, MD, Christian H Geisler, Marinus H.J. Van Oers, MD, PhD

Blood (2013) 122 (21): 2861.

https://doi.org/10.1182/blood.V122.21.2861.2861

Published: 2013

Journal Articles

CMV-Specific CD8 + T-CELL Function Is NOT Impaired In CLL

Doreen te Raa, MD, Fernanda Pascutti, PhD, Juan J Garcia-Vallejo, PhD, Emilie Reinen, Ester B.M. Remmerswaal, René A.W. Van Lier, PhD, Eric Eldering, PhD, Marinus H.J. Van Oers, MD, PhD, Sanne H. Tonino, MD PhD, Arnon P. Kater, MD PhD

Blood (2013) 122 (21): 2862.

https://doi.org/10.1182/blood.V122.21.2862.2862

Published: 2013

Journal Articles

Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial

Henk Lokhorst, Bronno van der Holt, PhD, Sonja Zweegman, MD PhD, Edo Vellenga, MD, PhD, Sandra Croockewit, MD, Marinus H.J. Van Oers, MD, PhD, Peter von dem Borne, MD, PhD, Pierre W. Wijermans, MD, PhD, M. R Schaafsma, MD, PhD, Okke de Weerdt, Shulamiet Wittebol, MD, Michel Delforge, MD, PhD, Gerard M.J. Bos, Prof MD PhD, Harm Sinnige, Marinus MarwijkKooy, Peter Joosten, MD, Monique C. Minnema, MD PhD, Rianne Ammerlaan, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 3332.

https://doi.org/10.1182/blood.V122.21.3332.3332

Published: 2013

Journal Articles

No Improvement Of Overall Survival After Extended Follow-Up Of Donor Versus No Donor Analysis Of Newly Diagnosed Myeloma Patients Included In The HOVON 50/54 Study

Henk Lokhorst, Bronno van der Holt, PhD, Jan Cornelissen, MD, PhD, Marie José Kersten, MD, PhD, Marinus H.J. Van Oers, MD, PhD, Reinier Raymakers, MD, PhD, Monique C. Minnema, MD PhD, Sonja Zweegman, MD PhD, Jeroen JWM Janssen, MD, Mark Zijlmans, MD, Gerard M.J. Bos, Prof MD PhD, Nicolaas PM Schaap, MD, PhD, Okke de Weerdt, Shulamiet Wittebol, MD, Rianne Ammerlaan, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 2132.

https://doi.org/10.1182/blood.V122.21.2132.2132

Published: 2013

Journal Articles

The Broad Kinase Inhibitor Dasatinib in Combination with Fludarabine in Patients with Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase 2 Study

Arnon P. Kater, MD PhD, Marjolijn Spiering, Rob D Liu, Marielle M Beckers, Sanne H. Tonino, Simon M. G. J. Daenen, Jeanette K Doorduijn, Nienke A Lankheet, Dieuwertje M Luijks, Doreen te Raa, MD, Eric Eldering, PhD, Marinus H.J. Van Oers, MD, PhD

Blood (2012) 120 (21): 1798.

https://doi.org/10.1182/blood.V120.21.1798.1798

Published: 2012

Journal Articles

Mapping the Targets of Dasatinib in Chronic Lymphocytic Leukemia Reveals Distinct Roles for Abl and Btk in Drug Resistance and Adhesion, and Explains Clinical Effects On Lymph Node Reduction

Eric Eldering, PhD, Christian R Geest, Martin FM de Rooij, Nora Liu, Bogdan I Florea, Marinus H.J. Van Oers, MD, PhD, Hermen S Overkleeft, Marcel Spaargaren, PhD, Arnon P. Kater, MD PhD

Blood (2012) 120 (21): 3900.

https://doi.org/10.1182/blood.V120.21.3900.3900

Published: 2012

Journal Articles

SF3B1 Mutations in CLL Are Equivalent to p53/ATM Dysfunction and Cause Defective Puma Upregulation in Response to Chemotherapy

Doreen te Raa, MD, Ingrid AM Derks, Dieuwertje M Luijks, Jacoline van Laar, Hanneke Monsuur, Ceri Oldreive, Alexander Jethwa, Jennifer Hüllein, Tatjana Stankovic, MD PhD, Thorsten Zenz, MD, Marinus H.J. Van Oers, MD, PhD, Arnon P. Kater, MD PhD, Eric Eldering, PhD

Blood (2012) 120 (21): 711.

https://doi.org/10.1182/blood.V120.21.711.711

Published: 2012

Journal Articles

C1-Inhibitor Rescues Red Blood Cells From Complement Mediated Destruction in Autoimmune Hemolytic Anemia

Diana Wouters, PhD, Stephan Femke, Masja de Haas, MD, PhD, Conny Brouwer, Paul Strengers, MD PhD, Anton Hagenbeek, MD, PhD, Marinus H.J. Van Oers, MD, PhD, Sacha Zeerleder, MD PhD

Blood (2011) 118 (21): 716.

https://doi.org/10.1182/blood.V118.21.716.716

Published: 2011

Journal Articles

Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial

Christian H Geisler, MD, PhD, Mars MB van 't Veer, MD, PhD, Wim van Putten, MSc, Jesper Jurlander, MD.PHD, Jan Walewski, MD, PhD, Geir Tjonnfjord, MD, PHD, Maija Itälä-Remes, MD, PHD, Eva Kimby, M.D., Ph.D., Tomas Kozak, MD, PhD, Aaron Polliack, MD, Shulamiet Wittebol, MD, Fokje Spoelstra, PhD, Marinus H.J. Van Oers, MD, PhD

Blood (2011) 118 (21): 290.

https://doi.org/10.1182/blood.V118.21.290.290

Published: 2011

Journal Articles

Role of T Cell-Derived IL-21 in the Proliferation of Chronic Lymphocytic Leukemia Cells,

Maria F. Pascutti, PhD, Jacqueline M. Tromp, MD, Margot Jak, MD, Ingrid A.M. Derks, Rene A.W. van Lier, PhD, Steven T. Pals, MD, PhD, Marinus H.J. Van Oers, MD, PhD, Arnon P Kater, MD, PhD, Eric Eldering, PhD

Blood (2011) 118 (21): 3871.

https://doi.org/10.1182/blood.V118.21.3871.3871

Published: 2011

Journal Articles

Variations of Noxa Levels Caused by p38 MAPK Signaling Result In Heterogeneous Sensitivity to ABT-737 In CD40L-Stimulated CLL Cells

Jacqueline M Tromp, MD, Christian R Geest, PhD, Judith Elias, Jacoline van Laar, Marinus H.J. Van Oers, MD, PhD, Eric Eldering

Blood (2010) 116 (21): 1825.

https://doi.org/10.1182/blood.V116.21.1825.1825

Published: 2010

Journal Articles

CD40 Stimulation Sensitizes CLL Cells to CD20-Triggered Cell Death by Rituximab and GA101 Via a Different Mechanism

Margot Jak, Gregor van Bochove, Christian Klein, PhD, Pablo Umana, PhD, Eric Eldering, PhD, Marinus H.J. Van Oers, MD, PhD

Blood (2010) 116 (21): 3979.

https://doi.org/10.1182/blood.V116.21.3979.3979

Published: 2010

Journal Articles

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non- Hodgkin’s Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

Marinus H.J. Van Oers, MD, PhD, Martine Van Glabbeke, Liliana Baila, MD, Livia Giurgia, Richard Klasa, Robert E Marcus, Max Wolf, Eva Kimby, Anton Hagenbeek

Blood (2008) 112 (11): 836.

https://doi.org/10.1182/blood.V112.11.836.836

Published: 2008

Journal Articles

Dichotomy in NF-κb Signaling and Chemoresistance in IgV H Mutated Versus Unmutated CLL Cells Revealed by CD40Ligand/CpG Stimulation

Jacqueline Tromp, Sanne H. Tonino, Marinus H.J. Van Oers, MD, PhD, Eric Eldering

Blood (2008) 112 (11): 542.

https://doi.org/10.1182/blood.V112.11.542.542

Published: 2008

Journal Articles

Platinum-Based Compounds Induce Expression of p73 and Restores Drug- Sensitivity in p53 Dysfunctional Chronic Lymphocytic Leukemia (CLL) Cells.

Sanne H. Tonino, MD, Chantal Mulkens, Yoshinori Nonomura, MD, Guangli Suo, MD, Thomas J. Kipps, MD, PhD, Marinus H.J. van Oers, MD, PhD, Eric Eldering, MD, Arnon P. Kater, MD, PhD

Blood (2008) 112 (11): 2102.

https://doi.org/10.1182/blood.V112.11.2102.2102

Published: 2008

NARROW

Patients with Chronic Lymphocytic Leukemia Belonging to the B-Cell Receptor Stereotypy Subset #2 Have Long Progression Free Survival after Chemo- or Chemoimmunotherapy in the HOVON68 Trial

Alpha1-Antichymotrypsin Present in Therapeutic C1-Inhibitor Products Competes with Selectin - Sialyl Lewis X Interaction

Individual Patient Data (IPD) Meta-Analysis of Rituximab Maintenance (MR) for Patients (pts) with Follicular Lymphoma (FL)

R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation

Possible Mechanisms Of Resistance To The Novel BH3-Mimetic ABT-199 In In Vitro Lymph Node Models Of CLL – The Role Of Abl and Btk

The Impact Of Subclonal Versus Clonal Novel Recurrent Mutations On Treatment Outcome In Previously Untreated High Risk CLL Patients: Results From The HOVON68 Trial

CMV-Specific CD8 + T-CELL Function Is NOT Impaired In CLL

Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial

No Improvement Of Overall Survival After Extended Follow-Up Of Donor Versus No Donor Analysis Of Newly Diagnosed Myeloma Patients Included In The HOVON 50/54 Study

The Broad Kinase Inhibitor Dasatinib in Combination with Fludarabine in Patients with Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase 2 Study

Mapping the Targets of Dasatinib in Chronic Lymphocytic Leukemia Reveals Distinct Roles for Abl and Btk in Drug Resistance and Adhesion, and Explains Clinical Effects On Lymph Node Reduction

SF3B1 Mutations in CLL Are Equivalent to p53/ATM Dysfunction and Cause Defective Puma Upregulation in Response to Chemotherapy

C1-Inhibitor Rescues Red Blood Cells From Complement Mediated Destruction in Autoimmune Hemolytic Anemia

Role of T Cell-Derived IL-21 in the Proliferation of Chronic Lymphocytic Leukemia Cells,

Variations of Noxa Levels Caused by p38 MAPK Signaling Result In Heterogeneous Sensitivity to ABT-737 In CD40L-Stimulated CLL Cells

CD40 Stimulation Sensitizes CLL Cells to CD20-Triggered Cell Death by Rituximab and GA101 Via a Different Mechanism

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non- Hodgkin’s Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

Dichotomy in NF-κb Signaling and Chemoresistance in IgV H Mutated Versus Unmutated CLL Cells Revealed by CD40Ligand/CpG Stimulation

Platinum-Based Compounds Induce Expression of p73 and Restores Drug- Sensitivity in p53 Dysfunctional Chronic Lymphocytic Leukemia (CLL) Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only